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A lzheimer disease (AD) represents the most common cause of dementia 1 and is characterized by cognitive and functional impairment, and neuropsychiatric disturbances. AD has been traditionally considered as a slowly progressive condition, with a survival of approximately 8 to 10 years, and an estimated cognitive decline of approximately 3 points per year at the Mini Mental State Examination (MMSE). 2, 3 Nevertheless, longitudinal studies and clinical trials have increasingly documented important intraindividual and interindividual variability, and different rates of progression have been described. Several factors may likely contribute to such reported clinical heterogeneity 4 : (1) true differences in the neurodegenerative processes and, thus, in the clinical course of the disease; (2) methodological aspects, such as diverse study populations, outcome measures, and times of observation; (3) different comorbidities and concomitant medications; and (4) social factors, such as different patient assistance, economic status, and accessibility to health care.
Predicting the course of cognitive decline may have important practical implications. First, it may help clinicians at more adequately addressing the questions and worries of newly diagnosed AD patients and their families concerning the duration of the disease and its trajectory over time. Moreover, it may reduce biases when conducting observational studies and clinical trials enrolling AD patients. In fact, their "natural" tendency to progress faster or slower should be considered when interpreting the study findings (eg, the effectiveness of the investigated treatment or intervention). 5 Finally, it has been argued that properly modeling the course of AD may facilitate the validation of putative biomarkers, better correlating with the rates of progression rather than with the severity of the disease.
To date, considerable attention has been addressed to the clinical definition and the characterization of rapidly progressive variants of AD. 3, 6, 7 This has led to the identification of several genetic (eg, ApoE genotype), sociodemographic (eg, age, sex, and education), and clinical factors (eg, focal neurological signs, specific neuropsychiatric disturbances, and visuospatial deficits) potentially anticipating a quick worsening of cognitive functioning. 3, 8, 9 Nevertheless, the available evidence is still conflicting and far from being conclusive. Surprisingly, less interest has been given to the clinical AD variants characterized by a slow cognitive decline, despite being seen commonly in routine clinical practice.
The present study aimed at evaluating whether the rate of cognitive worsening in AD may be predicted by widely available and easy-to-assess factors. Therefore, we measured the association between several sociodemographic and clinical variables and 3 different progression rates defined by modifications (over 1 year of follow-up) of the MMSE score in the Impact of Cholinergic Treatment USe (ICTUS) study.
METHODS

Study Design and Participants
The ICTUS study has been described previously elsewhere. 10, 11 In brief, the ICTUS study is a prospective multicenter cohort study aimed at evaluating the clinical course, treatment outcomes, and the socioeconomic impact of AD in Europe. It involved 29 participating centers from 12 European countries, all members of the European Alzheimer Disease Consortium, a network of clinical and research institutions specialized in the diagnosis and treatment of AD.
The following inclusion criteria were adopted in the ICTUS study: (1) diagnosis of probable AD made according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria 12 ; (2) a MMSE score ranging from 10 to 26; (3) living in the community with a well-identified informal caregiver; (4) the absence of known conditions reducing the patient's life expectancy to <2 years; (5) the ability to sign an informed consent. The study was approved by the Ethics Committee of the Toulouse University Hospital (coordinating center) and at individual centers by local or national ethical committees. All the study participants signed an informed consent.
After the baseline assessment (between February 2003 and July 2005), participants were followed up for 2 years with midterm reevaluations every 6 months. At baseline and at each follow-up visit, a comprehensive clinical and neuropsychological assessment was performed.
Present analyses were restricted to the first 12 months to improve the clinical meaningfulness of our findings. In fact, considering the nature of AD manifestations as well as the continuous modifications of its phenotype, it is more clinically relevant to explore short-term outcomes among affected patients than investigating the predictive capacities of parameters over a very long term. This approach could allow a timely prediction of short-term clinical trajectories, allowing clinicians to promptly plan and implement appropriate interventions. In parallel, we decided to limit our analyses to reduce as much as possible the effects of patients lost during follow-up due to (1) dropouts (a frequent occurrence in this kind of study participants) 13 and (2) mortality.
Overall, a total of 1375 patients were recruited in the ICTUS study. A total of 370 participants were excluded for the present analyses because they dropped out before the 12-month assessment. These patients were found to be not significantly different from those we considered in our study sample in terms of sociodemographic characteristics. Conversely, they were shown to be more cognitively [MMSE score: P = 0.04; Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) score: P < 0.001] and functionally [activities of daily living (ADL) score: P < 0.001; instrumental ADL (IADL) score: P < 0.001] impaired at baseline.
Cognitive Function Tests
The cognitive performance was assessed using MMSE 2 and ADAS-Cog. 14 MMSE includes 30 items focused at measuring different cognitive aspects (orientation, registration, attention, recall, and language). The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. This tool has been frequently adopted to categorize the rate of cognitive progression in AD patients. 3, 15 ADAS-Cog represents the most widely adopted cognitive outcome measure in AD trials. It includes 11 items assessing different cognitive domains (memory, language, and praxis). The total ADAS-cog score ranges from 0 to 70, with higher scores indicating greater cognitive impairment.
Cognitive Progression Groups
For the present analyses, ICTUS participants were grouped according to the cognitive modification (in terms of MMSE variation) occurring between the baseline and the 12-month follow-up assessments. In particular, participants were divided into 3 groups as follows: (1) "Slow" decline (ie, decrease in the MMSE score r1
point per year 16 ); (2) "Intermediate" decline (ie, decrease in the MMSE score between 2 and 5 points per year 3,17,18 ); and (3) "Rapid" decline (ie, decrease in the MMSE score Z6
points per year 3 ). We adopted MMSE to define these groups mainly because prediction models of decline have commonly used this variable as an outcome measure, providing a reference of what can be considered as a clinically meaningful cognitive decline. 19 Moreover, the widespread clinical use of MMSE may facilitate the understanding and the implementation of the results of this study. The choice of categorizing the MMSE score was motivated by the attempt of rendering our findings more clinical friendly. In fact, predicting a specific cognitive trajectory (ie, "slow," "intermediate," and "rapid"), rather than the loss of a certain amount of MMSE points (thus considering the MMSE score as a continuous variable), appears to be more appealing for clinicians approaching demented patients.
Functional Ability Tests
Physical function was assessed adopting the ADL 20 and the IADL 21 scales.
The ADL scale is a carer-administered questionnaire ranking the adequacy of performance in the 6 functions of bathing, dressing, toileting, transferring, continence, and feeding. Patients score 1 for independence in each of the 6 functions. Higher scores indicate greater functional independence.
The IADL scale is a carer-administered questionnaire assessing the adequacy of performance in the 8 tasks of using the telephone, shopping, preparing meals, housekeeping, doing laundry, using public transportation or driving, using medications, and handling finances. Patients score 1 for independence in each of the 8 tasks. Higher scores indicate greater functional independence.
Neuropsychiatric Symptoms
Neuropsychiatric symptoms were assessed with the 12item version of the Neuropsychiatric Inventory (NPI). 22 The NPI consists of a retrospective (up to 1 month) assessment of 12 neuropsychiatric symptoms commonly present in dementia. Each symptom is rated, when present, in terms of severity (ranging from 1, "mild" to 3, "severe") and frequency (ranging from 1, "occasionally" to 4, "very frequently"). The score of each item is then calculated by multiplying severity and frequency, thus obtaining a score ranging between 0 and 12. The total NPI score is finally obtained by adding all the single items scores (thus, ranging from 0 to 144), with higher scores indicating greater psychopathology.
Other Variables
Sociodemographic (age, sex, education, and income), clinical (family history of AD and AD duration; body mass index; self-reported diagnosis of diabetes, hypertension, ischemic heart disease, stroke, and seizures; parkinsonism, and focal neurological signs), and therapeutic (antidementia medications) data were recorded at the baseline assessment. The severity of dementia was assessed by the Clinical Dementia Rating (CDR) 23 scale. The Zarit Burden Interview 24 was adopted for evaluating the caregiver's burden.
Statistical Analysis
For the present analyses, participants were grouped according to their rate of cognitive decline between the baseline and the 12-month follow-up visits, as measured by MMSE score modifications. One-way analysis of variance and w 2 tests were used to describe continuous and categorical characteristics of the study sample across the 3 categories of cognitive decline. Multinomial logistic regression analyses were performed for estimating odds ratios (OR) and 95% confidence intervals (CI) of different continuous (ie, age, ADAS-Cog, IADL, NPI) and categorical (ie, sex, history of ischemic heart disease, history of hypercholesterolemia) independent indicators across the rate of "intermediate" and "rapid" cognitive decline, with "slow" decline as the reference group, as measured by MMSE score modifications over 1 year of follow-up. The selection of potential indicators in the statistical model was based on their significant difference across the 3 groups of cognitive progression. Statistical significance in the multinomial logistic regression analyses was defined as P < 0.05. Statistical analyses were performed using SPSS statistical software version 18.0.0 (IBM Corp., New York, NY).
RESULTS
Descriptive characteristics of the study sample at the baseline assessment are shown in Table 1 . A total of 1005 patients (women 64.5%) were considered for the present analyses. The sample population had a mean age of 76.1 (SD, 7.7) years. MMSE and ADAS-Cog scores at baseline were 20.6 (SD, 3.9) and 20.3 (SD, 8.9), respectively, indicating a mild to moderate cognitive impairment. Conversely, only 11% of the cohort exhibited a greater dementia severity (ie, CDR score Z2). Nearly half of patients had cholinesterase inhibitors (ChEIs) treatment.
At the 12-month visit, 523 participants (52.0%) showed a "slow" decline of cognitive performance. In total, 362 participants (36.0%) presented an "intermediate" decline, and 120 patients (12.0%) experienced a "rapid" cognitive worsening. The 3 groups were comparable with regard to their sociodemographic characteristics and comorbidities. Differences between groups were observed for CDR (P < 0.001), ADAS-Cog (P < 0.001), ADL (P = 0.09), IADL (P = 0.08), and NPI (P = 0.02) scores at baseline. In particular, participants exhibiting a "rapid" decline were found to be cognitively and functionally more impaired at the baseline. Moreover, "rapid" decliners had higher basal NPI scores, indicating a greater frequency and severity of behavioral disturbances, and a higher likelihood of receiving ChEI treatment (P = 0.08). Table 2 shows the results of a multinomial logistic regression analysis for "intermediate" and "rapid" decline having the group of participants showing a "slow" decline as reference group. Higher ADAS-Cog scores at baseline were significantly associated with both "intermediate" (OR, 1.04; 95% CI, 1.02-1.07) and "rapid" (OR, 1.07; 95% CI, 1.04-1.10) worsening after 12 months of follow-up. In contrast, increasing age was associated negatively with "rapid" cognitive decline (OR, 0.96; 95% CI, 0.93-0.99). Finally, higher NPI scores were found to predict the "intermediate" rate of cognitive decline (OR, 1.01; 95% CI, 1.00-1.03). Interestingly, the same trends were obtained when different cutoffs were used for grouping ICTUS participants according to their rate of cognitive decline (ie, "slow" decline: decrease in the MMSE score r2 point per year; "intermediate" decline: decrease in the MMSE score between 3 and 5 points per year; and "rapid" decline: decrease in the MMSE score Z 6 points per year).
When the predictors were standardized as per their SD (data not shown), we found that an increase of 7.7 years of age and of 8.9 points of ADAS-Cog were associated with 28.0% and 82.0% increased risks of following a "rapid" decline, respectively. In other words, the ADAS-Cog seemed to be a stronger predictor than age for "rapid" cognitive worsening.
DISCUSSION
In the present study, we explored whether common sociodemographic and clinical characteristics are able to predict the rate of cognitive decline in AD. Overall, most of the study participants exhibited a slow cognitive course of the disease. More severe cognitive impairment at the baseline was found to predict a faster cognitive decline over the 12 months of observation. In contrast, older age was found to be protective for such a "rapid" pattern of cognitive decline.
Longitudinal studies are increasingly documenting slow rates of progression among AD populations. 16, 17, 25 Moreover, it has already been shown that treatment with ChEIs increases the probability of a slow rate of cognitive decline significantly. 15 In our study, despite having adopted very strict criteria (ie, decrease in the MMSE score r1 point per year), such a slow rate of worsening was found to represent the most common cognitive trajectory (being observed in >50% of the ICTUS participants). The proportion of slow decliners was significantly higher than that observed in previous studies. 4, 15, 16 Slowly progressive variants of AD (defined according to the present operationalization) are probably less commonly observed in routine clinical practice compared with our study. This may support the hypothesis that patients participating in clinical trials and observational studies may be overall healthier (and, maybe, cognitively healthier) compared with the general population, 16, 26 thus experiencing a more favorable clinical course. In other words, the external validity (ie, generalizability) 27 of our findings should be confirmed in other studies.
Beside these preliminary considerations, the clinical characterization of slowly progressive AD seems to be of special interest. In fact, it could concur with the clinical identification of factors potentially associated with a more favorable course of the disease. Moreover, it could allow more adequately conducting and interpreting randomized controlled trials enrolling AD patients. In fact, the tendency of a sizeable proportion of participants to progress slower may bias the initial sample size analysis and/or the interpretation of the study findings. 5 For example, including more slow decliners in the treatment arm of an AD trial may lead to an overestimation of the effect size of the studied intervention. Conversely, if they are mostly allocated in the control group, this could reduce the chance of detecting a therapeutic effect.
In the present study, older age was found to be associated with a decreased likelihood of experiencing a faster worsening of cognitive functioning over the 12 months of follow-up. This result is in line with the available evidence related to the natural history of AD, mostly reporting an inverse association between the age at dementia onset and the rate of cognitive decline. 28, 29 This relationship has also been corroborated by several neuroimaging and neuropathologic findings. Magnetic resonance imaging studies have described faster rates of whole-brain and temporallobe atrophy among younger AD patients. 30 Pathologic studies have reported greater neuritic plaque burden and neurotransmitter deficits in early-onset compared with lateonset AD. 31 Accordingly, positron emission tomography studies have reported a greater amyloid load in patients with early-onset AD. 32 Finally, it has been observed that older individuals mostly develop specific histopathologic subtypes of AD (called "limbic-predominant AD") that are clinically characterized by a longer survival and a less steep decline of cognitive function. 33 On the basis of these considerations, the influence of age on the rate of cognitive decline should be considered properly when defining the study populations in AD trials.
Similar to the existing literature, initial cognitive impairment was found to predict an unfavorable course of the disease. In this regard, ADAS-Cog scores at baseline have been repeatedly shown to represent an important covariate affecting the rate of AD progression. 34 That is, the milder the baseline cognitive impairment in a population observed within a trial, the slower the disease progression, and vice versa. Interestingly, our data do not confirm previous evidence indicating education, neurological focal signs, parkinsonism, and a history of cerebrovascular disease as predictors of rapid cognitive progression. 3, 8, 9 Our study has several strengths. The analyses were performed in a large sample of AD patients, recruited at numerous dementia clinics across Europe. Moreover, taking into account the nonlinear AD progression over time, 25 we also considered the duration and the severity of dementia (as measured by the CDR score) as potential confounders. Nevertheless, some possible limitations of our analyses should be discussed as they may potentially influence our findings. First, the limited duration of the follow-up does not enable us to draw conclusions concerning the medium-term and the long-term history of cognitive decline in AD. Although the ICTUS study is characterized by a 2-year follow-up, we decided to limit the observation period to only the first 12 months. Such a choice is justified by the attempt to improve the clinical meaningfulness of our findings by drawing useful information for short-term outcomes (rather than for more uncertain medium-term and long-term endpoints). In fact, it is important to provide to physicians key criteria with which they can quickly and easily evaluate the risk of the patient for short-term clinical worsening. Second, several factors potentially affecting the overall health status of the participants (thus directly or indirectly influencing their cognitive function) were not taken into consideration in the present analyses. Therefore, we cannot exclude the fact that third factors not considered in our study might have affected or differently explained our findings. In particular, given the lack of genetic data, the impact of the ApoE genotype, well known to strongly influence not only the risk of developing AD but also its clinical manifestations and course, was not explored. 35 Moreover, several factors that have already been found to affect the natural history of AD (eg, neuropsychiatric disturbances) are themselves influenced by ApoE genotype. 36 A further potential limitation is represented by the adoption of a single measure (ie, the MMSE score) to define the rate of cognitive decline. Despite being widely adopted, MMSE does not reflect global cognitive functioning comprehensively and accurately (eg, it does not assess executive abilities).
In conclusion, a slow progression of cognitive decline is common among AD patients. The clinical characterization of the slowly progressive AD variants may have important practical implications, both in the clinic and in research settings. In particular, age and cognitive function should always be considered carefully when designing trials on AD and defining study populations. Further studies are needed to confirm and extend the present findings.
